作者
Eduardo Tolosa, Irene Litvan, Günter U Höglinger, David Burn, Andrew Lees, María V Andrés, Belén Gómez‐Carrillo, Teresa León, Teodoro Del Ser, TAUROS Investigators, JC Gómez, B Tijero, K Berganzo, J García de Yebenes, JL Lopez Sendón, G Garcia, E Tolosa, MT Buongiorno, N Bargalló, JA Burguera, I Martinez, J Ruiz‐Martínez, I Narrativel, F Vivancos, I Ybot, M Aguilar, P Quilez, M Boada, A Lafuente, I Hernandez, JJ López‐Lozano, M Mata, A Kupsch, A Lipp, G Ebersbach, T Schmidt, K Hahn, G Höglinger, M Höllerhage, WH Oertel, G Respondek, M Stamelou, H Reichmann, M Wolz, C Schneider, L Klingelhöfer, D Berg, W Maetzler, KK Srulijes, A Ludolph, J Kassubek, M Steiger, K Tyler, DJ Burn, L Morris, A Lees, H Ling, R Hauser, T McClain, D Truong, S Jenkins, I Litvan, D Houghton, J Ferrara, Y Bordelon, A Gratiano, L Golbe, M Mark, R Uitti, J Ven Gerpen
发表日期
2014/4
期刊
Movement Disorders
卷号
29
期号
4
页码范围
470-478
简介
It is believed that glycogen synthase kinase‐3 (GSK‐3) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) study was a double‐blind, placebo‐controlled, randomized trial to assess the efficacy, safety, and tolerability of tideglusib, a GSK‐3 inhibitor, as potential treatment for PSP. The study enrolled 146 PSP patients with mild‐to‐moderate disease who were randomized to receive once‐daily 600 mg tideglusib, 800 mg tideglusib, or placebo (ratio, 2:2:1) administered orally over 52 weeks. The primary endpoint was the change from baseline to week 52 on the PSP rating scale. Secondary endpoints were safety and tolerability of tideglusib, changes in motor function (the Timed Up and Go Test), cognition (Dementia Rating Scale‐2, Frontal Assessment Battery, verbal fluency), apathy (Starkstein scale), activities of daily living (Schwab and England scale …
学术搜索中的文章
E Tolosa, I Litvan, GU Höglinger, D Burn, A Lees… - Movement Disorders, 2014